BenevolentAI
ExitedBenevolentAI is a clinical-stage AI drug discovery company that combines advanced AI and machine learning with science to discover and develop novel and more effective medicines.
London, UKbenevolent.ai ↗
Total raised
€99M
€98,900,000
Funding rounds
1
Investors
1
distinct backers
Active since
2018-01
latest 2018-01
Funding by year
EUR raised per yearFunding rounds
1 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2018-02-01 | Other | €99M | Woodford Investment Management | View deal → |
Exit
Type
ipo
Date
Dec 2021
Value
€435M
Acquiror
—
Investors
1Related news
- Europe’s largest SPAC merger: UK’s BenevolentAI to list on Euronext Amsterdam via €1.5B SPAC dealsiliconcanals.com · 2021-12
- pehub.com